SLC5A2 and diabetes mellitus: Sodium-glucose cotransporter-2 (SGLT2)inhibitors, which were developed originally for diabetes, have been shown tobenefit patients with heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) by enhancing myocardial energy efficiencyand reducing cardiac fibrosis [42].